ABT-288
/ AbbVie
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 29, 2025
Rat and dog quad-culture liver chip models: Characterization and use to interrogate a potential flavin-containing monooxygenase-mediated, species-specific toxicity of a histamine receptor antagonist.
(PubMed, Toxicol Sci)
- "Species differences in N-oxidation were not observed in rat and dog liver microsomes or 2D hepatocyte monocultures, suggesting that properties of the quad-culture MPS were necessary to model higher FMO activity observed in dogs in vivo. The data suggest that this preclinical species liver chip model provides novel understanding of vitro to in vivo translation of ABT-288 dog liver toxicity."
Journal • Preclinical
June 26, 2025
Efficacy and Safety of Histamine H3 Receptor Antagonist/Inverse Agonist Including Betahistine for Schizophrenia: A Systematic Review and Meta-Analysis.
(PubMed, Neuropsychopharmacol Rep)
- "Some H3R-ANTs/H3R-IAs might provide benefit for the treatment of cognitive symptoms and depressive symptoms in individuals afflicted with schizophrenia."
Clinical • Journal • Retrospective data • Review • CNS Disorders • Insomnia • Psychiatry • Schizophrenia • Sleep Disorder
1 to 2
Of
2
Go to page
1